ATOSSA THERAPEUTICS, INC. analysts consensus, targets, ratings and recommendations | Nasdaq: ATOS | Nasdaq Atossa Therapeutics stock extended its recent gains on Thursday. 3.2100 -0.08 (-2.43%)Pre-Market: 5:21AM EST, SEATTLE, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical needs in oncology and infectious diseases, with a current focus on breast cancer and COVID-19, today issued the following letter from President and CEO Dr. Steven C. Quay to Atossa stockholders: To Our Valued Stockholders: With the onset of COVID-19, the year 2020 will be remembered as one that changed the entire paradigm of business, the way we lead our daily lives and the world. About the Atossa Therapeutics, Inc. stock forecast. In the second quarter 2021, we plan to report final data from our Australian window of opportunity Phase 2 study and obtain input from the FDA for further development in the U.S. Subject to receiving all regulatory clearances, we plan to commence a Phase 2 study of oral Endoxifen to reduce MBD in Stockholm as soon as COVID-19 restrictions allow. Atossa Therapeutics was founded in 2009 and its headquarters is located in Seattle, Wash. Shares of Atossa Therapeutics (ATOS) have done what shares of most companies in the hunt for coronavirus solutions have done in 2020 â appreciate. Atossaâs current focus is on breast cancer and COVID-19. In addition to developing AT-301 nasal spray for COVID-19 patients recently diagnosed with the disease, we believe a significant opportunity exists for the nasal spray to potentially prevent COVID-19 in high-risk environments, such as people living with an infected patient, people living and working in healthcare facilities, emergency responders or teachers. Results to date from this open-label study are sufficiently compelling that we have halted the study, shortening our development time-line by approximately one year. Moving forward in 2021, we will continue to pursue our mission with vigor and dedication and we have set the following goals and milestones: COVID-19 Therapies. While much work still lies ahead, we are pleased to report the following highlights of our progress: AT-301 Nasal Spray for the Treatment of COVID-19. Who is Atossa Therapeutics, Inc.âs transfer agent? We are in the process of identifying potential partners for this program. Six out of the initial six (100%) patients experienced a significant reduction in Ki-67 and each had a Ki-67 below 25% after treatment, which is the threshold identified in research by others for predicting overall survival. The high price target for ATOS is $8.00 and the low price target for ATOS is $7.00. For these reasons, we believe therapies like ours will provide valuable protection even as vaccines continue to be developed and deployed. We expect to receive regulatory approval in the first quarter 2021 to commence additional pre-clinical and clinical studies of AT-H201 in Australia. Atossa Therapeutics, Inc. (ATOS) registered a 8.44% upside in the last session and has traded in the green over the past 5 sessions. 3.2100 -0.08 (-2.43%)Pre-Market: 5:21AM EST, Subscribe to Premium to view Fair Value for ATOS. The companyâs stock price has collected 76.02% of gains in the last five trading sessions. With its Forward Dividend at 0 and a yield of 0%, the companyâs investors could be worried for the ATOS stock to lose ahead of the earnings release. December 31st. During the past twelve months, despite the pandemic and the associated global disruptions, we continued to deliver on our corporate and clinical milestones, expanded our pipeline, and significantly strengthened our balance sheet by adding approximately $81 million in net proceeds. I am deeply saddened by the devastating loss of life and the countless challenges the pandemic has created worldwide. © 2021 Verizon Media. It is understandable that investor optimism is growing ahead of the companyâs current quarter results. Get the hottest stocks to trade every day before the market opens 100% free. Forward-Looking Statements Disclaimer Statement Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer ⦠Following surgery, an additional compassionate use authorization was granted by the FDA for the same patient, who has now continued to take oral Endoxifen in the adjuvant setting following her surgery. Update: Atossa Therapeutics Inc (NASDAQ: ATOS) shares started the second day of the week on the back foot after losing 0.77% on Monday. Since the turn of the year, there has ⦠Sincerely, Steven C. Quay, MD, Ph.D.President and Chief Executive Officer About Atossa Therapeutics Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focus on breast cancer and COVID-19. VStock Transfer, LLC 77 Spruce Street Suite 201 Cedarhurst, NY 11516 855-9VSTOCK 646-536-3179 info@vstocktransfer.com www.VStockTransfer.com. Currency in USD, Here's Why We're A Bit Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation, Atossa Stock at $8 a Share? We expect to release final data from this study in the first quarter of 2021 and then quickly start additional pre-clinical and clinical studies to support an investigational new drug application (IND) with the FDA. Atossa has two programs to develop therapies to treat COVID-19: One called the COVID-19 HOPE Program which uses AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators and another called AT-301 Nasal Spray for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms ⦠The company report on July 27, 2020 that Registration Is Now Open for Atossa Therapeuticsâ Tribe Public Webinar Presentation and Q&A Event on July 30, 2020. Company Contact:Atossa Therapeutics, Inc.Kyle Guse, CFO and General CounselOffice: 866 893-4927kyle.guse@atossainc.com Investor Relations Contact:Core IROffice:(516) 222-2560ir@atossainc.com, Tip: Try a valid symbol or a specific company name for relevant results, NasdaqGS - NasdaqGS Real Time Price. The study is subject to approval by the European Medical Product Authority and ethics board. The stock touched a ⦠On Wednesday, Atossa's shareholders received more good news. In May 2020, we reported interim results from our Phase 2 study in Australia showing a statistically significant (p=0.031) reduction of about 74% in tumor cell proliferation was achieved in the initial patients, as measured by Ki-67, over an average 22 days of dosing. SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announces updated findings following 26 months of Expanded Access (or "compassionate ⦠When is Atossa Therapeutics, Inc.âs fiscal year end? Forward-Looking Statements Disclaimer Statement Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Image source: Getty Images. Atossa Therapeutics Inc. ATOS 3.31 0.17 (4.89%). Find real-time ATOS - Atossa Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Deliver On Growth Plans? The Company is focused on developing therapeutics and delivery methods for breast cancer and other breast conditions. Their average twelve-month price target is $7.50, predicting that the stock has a possible upside of 106.04%. Atossa Therapeutics' stock is trading down $0.29 today. The AT-H201 components were found to be at least four times more potent than remdesivir and at least 20 times more potent than hydroxychloroquine. The share float percentage for the stock currently stands at 6.49%. For example, an ideal partner may be selling diagnostic tests for COVID-19 so that our nasal spray could be co-promoted with the diagnostic test once all regulatory approvals are obtained. About Atossa Therapeutics Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in ⦠In the last trading session, 24,019,020 shares of the Atossa Therapeutics, Inc. (NASDAQ:ATOS) were traded, and its beta was 2.29. Atossa Therapeutics Inc. (ATOS) is up over 12% at $3.66 in pre-market hours today, adding to yesterday's gain of 16%. New deadlier and/or more infective variants of COVID-19 are being reported in the U.S. and in many other countries and it is not clear that current vaccines will be completely effective against these and future variants. This study will evaluate safety, tolerability and efficacy of our oral Endoxifen. While we hope that traditional vaccines will be effective in reducing COVID-19 infections, it is also clear to us that therapies such as AT-301 nasal spray will also play an important role, particularly as it becomes clear that it will take months or years for vaccines to be administered around the world. Currency in USD, Trade prices are not sourced from all markets. “We are very encouraged by this patient’s experience with our Endoxifen over the past two years. Find the latest on short interest for Atossa Therapeutics, Inc. Common Stock (ATOS) at Nasdaq.com. Oral Endoxifen to Reduce Mammographic Breast Density (MBD). Per Hall, M.D., Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet. Atossa Therapeutics, Inc., which has a market valuation of $249.08 Million, is expected to release its quarterly earnings report Mar 24, 2021- Mar 29, 2021. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Atossa Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data Atossa Therapeutics's ATOS shares and potentially its market environment have been in a ⦠The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. We expect to open this study in Stockholm soon after receiving all necessary regulatory approvals, provided COVID-19 restrictions are lifted to permit patient recruitment. Atossa Therapeutics NASDAQ: ATOS is a Seattle-based clinical-stage biopharmaceutical company. We have contracted with South General Hospital in Stockholm to conduct a randomized, double-blinded, placebo-controlled Phase 2 study to reduce MBD in pre-menopausal women dosed over six months. She has now taken Atossa’s oral Endoxifen for approximately 26 months and is continuing to take oral Endoxifen daily under these authorizations. Atossa Therapeutics Inc. [NASDAQ: ATOS] stock went on an upward path that rose over 9.57% on Wednesday, amounting to a one-week price increase of more than 4.82%. “To date, the patient has not had a recurrence of breast cancer, as assessed by clinical breast examination and mammography; has not had treatment-related changes in periodic laboratory blood tests and general clinical examinations; and, the treatment has been well tolerated, including an absence of typical vasomotor symptoms commonly associated with tamoxifen (for example, night sweats and hot flashes), an FDA-approved drug frequently prescribed for breast cancer treatment,” commented Sidney Goldblatt, M.D., Principal Investigator. Atossa Therapeutics, Inc. (NASDAQ:ATOS)âs Major holders. AT-301 is a nasal spray being developed for at-home treatment of patients diagnosed with COVID-19 who do not require hospitalization. As of 2021 February 11, Thursday current price of ATOS stock is 3.555$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception).. Atossa Therapeutics, Inc. has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame. The one-year Atossa Therapeutics Inc. stock forecast points to a potential upside of 41.76. We are in a strong position to continue the development of our programs and opportunistically add accretive programs as we move forward. Fundraising Activities. The stockâs 5-day price performance is 41.53%, and it has moved by 94.19% in 30 days. Her experience serves as a model for ongoing development efforts.” About Atossa Therapeutics Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. It is intended to improve compromised lung function for moderate to severely ill, hospitalized COVID-19 patients by inhalation. Its pipeline includes two programs: endoxifen and intraductal microcatheter technology. The combined purchase price for ⦠Atossa Therapeutics Inc () Stock Market info Recommendations: Buy or sell Atossa Therapeutics stock? Most recently the companyâs share price was $2.37, and it changed around $0.16 or 0.07% from the last close, which brings the market ⦠Who are Atossa Therapeutics, ⦠Ki-67 is a recognized standard measurement of breast cancer cell proliferation. Oral Endoxifen. All rights reserved. The average equity rating for ATOS stock is currently 2.00, trading closer to a bullish pattern in the stock market. Atossa Therapeutics Inc. (NASDAQ:ATOS) went down by -10.16% from its latest closing price compared to the recent 1-year high of $5.08. In 2020, we made tremendous progress developing oral Endoxifen in the window of opportunity between diagnosis of breast cancer and surgical treatment. Analyst Report: Agilent Technologies, Inc. Analyst Report: Laboratory Corporation of America Holdings, Tip: Try a valid symbol or a specific company name for relevant results, NasdaqGS - NasdaqGS Real Time Price. With the ease of transmission, new variants emerging and the current limits of vaccines, we believe COVID-19 will be with us for the foreseeable future and we aim to be a part of the solution. At the end of this year and moving into the beginning of 2021, Atossa raised in excess of $81 million, which comfortably positions the Company to conduct its current programs through 2021 and beyond. To short Atossa Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender.
Geb Ability Build, Delete Intuit Account, Pepperidge Farm Chocolate Chip Cookies Calories, Beefsteak Tomato Vs Roma, Used Lawn Tractors For Sale Near Me, Warlock Leveling Spec Classic, Dirty Dancing Font, T2 Loose Leaf Gift Cube,